Subscribe
Sign In
Tag: CBT > DEA Scheduling: Page 7
Interviews & Opinion
A Positive Sign For Schedule III
In Vienna, a U.S. state department legal adviser champions member-state discretion over domestic drug policy, potentially removing the obstacle the Single Convention drug treaty could pose to cannabis reform.
November 7, 2023
Cannabis Rescheduling
31 Bipartisan House Lawmakers Urge DEA to End ‘Failed’ Cannabis Prohibition
A group of U.S. representatives sent a letter to DEA Administrator Anne Milgram calling on her agency to “recognize the merits of full descheduling.”
November 1, 2023
Cannabis Rescheduling
Rescheduling Cannabis: Would 1961 Drug Treaty Be a Possible Wrench?
Reclassifying cannabis to a Schedule III drug would put the U.S. in noncompliance with the international treaty Single Convention on Narcotic Drugs, 1961. Will this create a barrier for the U.S. in its scheduling review, and if so, to what extent? Historian James H. Mills weighs in.
October 5, 2023
Cannabis Rescheduling
‘Descheduling Would Not Be Utopia’
Shane Pennington of Porter Wright Morris & Arthur addresses some of the biggest questions and concerns surrounding cannabis rescheduling, including the role of the FDA and Big Pharma.
September 26, 2023
Interviews & Opinion
Opinion: HHS Rescheduling Recommendation is 'About Damn Time'
The U.S. Department of Health and Human Services recognition that cannabis should no longer be classified in the same category as heroin is an event to be celebrated. But the trajectory of U.S. policy deserves to be mourned.
September 20, 2023
Cannabis Rescheduling
'Descheduling Would Not Be Utopia'
Shane Pennington of Porter Wright Morris & Arthur addresses some of the biggest questions and concerns surrounding cannabis rescheduling, including the role of the FDA and Big Pharma.
September 13, 2023
Cannabis Industry Research
The Impacts of Cannabis Rescheduling: Panelists Weigh In During International Cannabis Bar Association Webinar
Industry legal experts Khurshid Khoja, Amber Littlejohn and Shane Pennington shared insight into what rescheduling could mean for taxes, research and federal enforcement.
September 12, 2023
Colorado
Colorado Governor to President Biden: ‘We Must Do Better’ on Federal Cannabis Reform
Gov. Jared Polis encouraged the president to move swiftly to reschedule cannabis and urged him to not let up on other incremental changes.
September 5, 2023
Cannabis Rescheduling
‘Rescheduling is Not Enough,’ And Other Reactions to HHS Recommendation on Cannabis
Cannabis industry responds with cautious optimism to the Department of Health and Human Services' call to reschedule the plant, noting the significance of the announcement but also the potential limitations of the move.
September 5, 2023
Cannabis Rescheduling
US Health and Human Services Department Recommends Cannabis Reclassified to Schedule III
The move from Schedule I to Schedule III would provide that cannabis has a federally accepted medical use, but the decision now goes to the DEA.
August 30, 2023
Interviews & Opinion
Opinion: Rescheduling Is Recriminalizing, Descheduling Is Decriminalizing
President of cannabis genetics company DNA Genetics, Rezwan Khan, weighs in on Biden's cannabis policy reform plan and how rescheduling or descheduling the plant would impact the industry.
August 29, 2023
Hemp Regulations in U.S.
DEA May Propose Regulations That Would Threaten the Hemp-Derived Cannabinoid Industry and Cast a Dark Cloud Over CBD Industry
The federal agency announced in early May that it plans to soon propose new rules that would classify synthetically derived cannabinoids as controlled substances and would decontrol CBD up to 0.1% THC on a weight-to-weight or weight-to-volume basis.
May 26, 2023
Previous Page
Page 7 of 8
Next Page